STOCK TITAN

Johnson & Johnson - JNJ STOCK NEWS

Welcome to our dedicated news page for Johnson & Johnson (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Johnson & Johnson's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Johnson & Johnson's position in the market.

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) declares a cash dividend of $1.19 per share for the first quarter of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
dividends earnings
-
Rhea-AI Summary
Johnson & Johnson (JNJ) faces mounting legal challenges as recent meso settlements confirm culpability and financial obligation to thousands of women who developed cancer from talc exposure. Attorneys representing ovarian cancer victims warn that J&J's bankruptcy strategy will not succeed, with upcoming jury trials in 2024 and recent limited settlements confirming the presence of cancer-causing asbestos in talc products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) will host a conference call on January 23rd to review fourth-quarter results. Joaquin Duato, Chairman and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer, and Jessica Moore, Vice President, Investor Relations will host the call. The webcast and presentation material will be accessible at Johnson & Johnson’s website. A replay of the webcast will be available. Telephone dial-in numbers are provided for both U.S. and international participants. The press release will be available the morning of the conference call. Please note the first-quarter date of Tuesday, April 16th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
conferences earnings
Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) to participate in the 42nd Annual J.P. Morgan Healthcare Conference. Joaquin Duato, Chairman and CEO, to represent the company in a session on January 8th, 12:45 p.m. (Eastern Time). Audio webcast available on www.investor.jnj.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
-
Rhea-AI Summary
Company XYZ (XYZ) Announces Strategic Partnership with ABC Corp - Press Release Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) presents long-term operational sales outlook, expecting 5-7% CAGR for 2025-2030 in both Enterprise and Innovative Medicine, with potential peak year sales assets of $5B+ and $1-5B. MedTech anticipates upper-range market growth of 5-7% through 2027. Company guides 2024 operational sales growth of 5-6% and adjusted operational EPS of $10.55-$10.75, reflecting 7.3% growth at the midpoint.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
Rhea-AI Summary
Johnson & Johnson (JNJ) appoints Eugene A. Woods, CEO of Advocate Health, to its Board of Directors. Woods brings extensive experience in leading and transforming healthcare systems, prioritizing high-quality patient care, and advocating for equitable healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
management
-
Rhea-AI Summary
Johnson & Johnson MedTech (JNJ) acquires Laminar, Inc., a medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). The acquisition was completed for an upfront payment of $400 million, with additional potential clinical and regulatory milestone payments in 2024 and beyond. Laminar's innovative approach uses rotational motion to eliminate the LAA, different from current commercial catheter-based procedure devices. Laminar recently received FDA approval for the U.S. pivotal study, which will begin enrollment in early 2024. The acquisition will require an in-process research and development charge, reducing operational and reported Adjusted EPS by approximately $0.17 from guidance previously issued for fiscal year 2023. The new expected operational and reported Adjusted EPS ranges for 2023 are now $9.85 to $9.91 and $9.90 to $9.96, respectively. Additionally, the asset acquisition is expected to have an approximate negative $0.15 EPS impact in fiscal year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
acquisition
-
Rhea-AI Summary
JNJ: Johnson & Johnson Settles Talcum Powder Trials in California. Attorney Leading Fight Highlights Implications. Beasley Allen Law Firm's Andy Birchfield asserts that J&J's decision to settle two talcum powder trials in California undermines the company's claim that bankruptcy is the only way to resolve over 50,000 lawsuits. The settlements also demonstrate that J&J is acknowledging its talc products contain asbestos. The attorney calls for J&J to rethink its legal strategies and emphasizes the importance of continued scrutiny and accountability in pursuing justice for those affected by talcum powder products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review on December 5, 2023, to share detailed reviews of its Innovative Medicine and MedTech businesses, long-term growth strategy, and value delivery to shareholders. The event will feature presentations from Company leaders and Q&A sessions. Virtual attendance is available, with a replay and supporting content to be posted by the end of the day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
conferences
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Stock Data

381.20B
2.40B
0.09%
71.28%
0.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New Brunswick

About JNJ

Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.